Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO)

Thoracic Cancer

Olcun Umit Unal¹⁰  Ilhan Oztop²  Nurgul Yasar⁹  Zuhat Urakci⁶  Tahsin Ozatli⁵  Oktay Bozkurt⁷  Alper Sevinc³  Yusuf Gunaydin⁸  Burcu Yapar Taskoylu¹  Erkan Arpaci^10,14  Arife Ulas^10,12  Hilmi Kodaz^10,11  Onder Tonyali⁸  Nilufer Avci^10,13  Asude Aksoy^4,10 

[1] Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, Turkey;Division of Medical Oncology, Department of Internal Medicine, Dokuz Eylul University Medical Faculty, Izmir, Turkey;Department of Medical Oncology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey;Department of Medical Oncology, Firat University Faculty of Medicine, Elazig, Turkey;Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Training and Research Hospital, Ankara, Turkey;Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Turkey;Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey;Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey;Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey;Division of Medical Oncology, Department of Internal Medicine, Ataturk University Medical Faculty, Erzurum, Turkey;Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey;Department of Medical Oncology, Ali Sonmez Oncology Hospital, Bursa, Turkey;Department of Medical Oncology, Balikesir Goverment Hospital, Balikesir, Turkey;Department of Medical Oncology, Sakarya Education and Research Hospital, Sakarya, Turkey

关键词: Primary thoracic soft tissue sarcoma;    prognostic factors;    treatment;   

DOI  :  10.1111/1759-7714.12150

来源: Wiley

【 摘 要 】

Abstract

Background

Soft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information is available. This study aimed to identify the prognostic factors for thoracic STSs and evaluate the disease's clinical outcomes.

Methods

The medical records of 109 patients with thoracic STSs who were treated between 2003 and 2013 were retrospectively reviewed. Patients' survival rates were analyzed and potential prognostic factors evaluated.

Results

The median follow-up period was 29 months (range: 1–121 months). STSs were most frequently localized on the chest wall (n = 42; 38.5%) and lungs (n = 42; 38.5%). The most common histological types were malignant fibrous histiocytoma (n = 23; 21.1%), liposarcoma (n = 17; 15.6%), and leiomyosarcoma (n = 16; 14.7%). The median survival time of all patients was 40.3 months (95% confidence interval, 14.22–66.37 months), with one and five-year survival rates of 93.4% and 63.5%, respectively. Univariate analysis of all groups revealed that metastatic stage, unresectability, tumor diameter of >10 cm, tumor location other than the chest wall, and grade 3 diseases were predictable of poor survival. However, only grade 3 diseases and tumor location other than the chest wall were confirmed by multivariate analysis as poor prognostic factors.

Conclusions

Primary thoracic STSs are rarely seen malignant tumors. Our results indicated that patients with low-grade tumors and those localized on the chest wall often experienced better survival outcomes.

【 授权许可】

CC BY-NC   
© 2014 The Authors. Thoracic Cancer published by Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.